 |
> 2003 Publications
21.
SEARCH Database Study Group Comparison of percentage of
total prostate needle biopsy tissue with cancer to percentage
of cores with cancer for predicting PSA recurrence after radical
prostatectomy: results from the SEARCH database.
Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti
JC Jr, Dorey F, Terris MK;
Urology. 61:742-7, 2003. 
PDF |
|
22.
Pretreatment total testosterone level predicts pathological
stage in patients with localized prostate cancer treated with
radical prostatectomy.
Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C,
Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D,
Donahue T:
J Urol, 169:1670-5, 2003. 
Abstract
|
PDF |
23.
Pentosan polysulfate decreases prostate smooth muscle
proliferation and extracellular matrix turnover.
Elliot SJ, Zorn BH, McLeod DG, Moul JW, Nyberg L, Striker LJ,
Striker GE:
Prostate Cancer Prostatic Dis., 6:138-42.
Abstract
|
24.
The current art of prostate needle biopsy.
Donahue T, Moul J:
Contemporary Urology, 15:72-81, 2003. Abstract |
25.
The role of hormonal therapy for PSA-only recurrence of
PCA after local therapy.
Moul JW, Zlotta AR:
Contemporary Urology, 15:31-36, 2003. |
26.
Temporarily Deferred Therapy (watchful waiting) for Men
Younger Than 70 Years and With Low-Risk Localized Prostate
Cancer in the Prostate-Specific Antigen Era.
C Carter, T Donahue, L Sun, H Wu, D. McLeod, C Amling, R Lance,
J Foley, W Sexton, L Kusuda, A Chung, D Soderdahl, S Jackman,
and JW. Moul
Jour Clin Oncology, Vol 21, No 21 (November 1), 2003: pp
4001-4008.
Abstract
|
PDF
|
27.
Diagnostic Potential of Prostate-specific Antigen Expressing
Epithelial Cells in Blood of Prostate Cancer Patients.
Chun-Ling Gao, Sudhir K. Rawal, Leon Sun, Amina Ali, Roger R.
Connelly, Lionel L. Bañez, Isabell A. Sesterhenn, David
G. Mcleod, Judd W. Moul, and Shiv Srivastava
Clinical Cancer Research, Vol. 9, 2545–2550, July
2003.
Abstract
|
PDF |
28.
p53 Immunostaining guided laser capture microdissection
(p53-LCM) defines the presence of p53 gene mutations in focal
regions of primary prostate cancer positive for p53 protein.
GL Griewe, RC Dean, W Zhang, D Young, IA Sesterhenn,
N Shanmugam, DG McLeod1, JW Moul, S Srivastava
Prostate Cancer and Prostatic Diseases (2003) 6, 281–285.
Abstract
|
PDF
|
29.
Evolution of therapeutic approaches with luteinizing hormone-releasing
hormone agonists in 2003.
JW. Moul, JE Fowler, Jr.
Urology 62 (Supplement 6A), December 22, 2003.
PDF
|
 Back
to Top |  Previous
Page |
|
